Health Care Distributors

China Meheco

China Meheco released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 8.189 B, actual EPS CNY 0.1218

China Meheco released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 9.467 B, actual EPS CNY 0.0123

China Meheco released FY2025 Annual Earnings on April 24 After-Market (BJT), Actual Revenue: CNY 35.36 B, Actual EPS: CNY 0.3164

China Meheco FY2026 Q1 Earnings Release on April 29 After-Market (BJT)

China Meheco to Release FY2025 Earnings on April 25 After-Market (BJT)

China Meheco released FY2025 Q3 earnings on October 27 During-Market BJT, actual revenue CNY 8.819 B, actual EPS CNY 0.1075

China Meheco released FY2025 9 Months Earnings on October 27 During-Market BJT, actual revenue CNY 25.89 B, actual EPS CNY 0.3039

China Meheco FY2025 Q3 Earnings Release on October 28, 2025 During-Market (BJT)

Trump Administration Drafting Order Impacting Sino-US Biopharma Deals

China Meheco released FY2025 Semi-Annual Earnings on August 27 During-Market (BJT), Actual Revenue: CNY 17.08B, Actual EPS: CNY 0.1965

China Meheco released FY2025 Q2 earnings on August 27 During-Market BJT, actual revenue CNY 8.813 B, actual EPS CNY 0.0852

China Meheco to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

National Medical Insurance Bureau Holds Seminar to Support Innovative Pharmaceutical and Medical Device Development

China Pharma's Subsidiary Tianfang Gets Approval for Fudostatin Tablets

Top 100 Pharmaceutical Companies' Revenue Continues to Fall but R&D Spending Hits New High

Tianfang Pharmaceutical Receives Approval Notice for Urapidil API Marketing Application

Tianfang Pharmaceutical's Clindamycin Phosphate Injection Passes Consistency Evaluation

China Medicine Subsidiary Tianfang Pharmaceutical Obtains Registration Certificate for Urapidil Hydrochloride Injection

Sanyo Pharmaceutical Receives Approval for Cervical Ecbolamin Injection

NMPA Issues Draft for Optimizing Clinical Trial Approval for Innovative Drugs

000028

600056

600511

Sinopharm Group Co. has reported its 2025 financial results for its subsidiary, China National Medicines Corporation. Revenue increased by 3.7% to RMB 52.47 billion, while net profit fell slightly by 0.18% to RMB 1.997 billion, with earnings per share remaining stable. The subsidiary improved cash flow, with net operating cash flow rising by 20.88%. Despite a decline in return on net assets, total assets grew by 5.03%. Analysts rate the stock as a Buy with a target price of HK$23.00.

Tip Ranks

Sinopharm Accord

SINOPHARM(CNCM LTD)

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Tianhong CNI BIOMEDICINE ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

China Universal 800 Health Care ETF

Guotai CSI Bio-medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Sinopharm Subsidiary Posts 2025 Revenue Growth Amid Flat Earnings and Stronger Cash Flow

JP Morgan's report indicates that innovative drugs from China have evolved from a "optional configuration" to a category of sources that multinational pharmaceutical companies must systematically evaluate during the asset screening phase. In certain oncology, autoimmune, and metabolic indications, some Chinese pharmaceutical companies' projects have already entered the forefront of global competition for the same targets. This leadership is not reflected in the innovation of mechanisms themselves, but more in clinical execution efficiency, patient enrollment speed, and the pace of indication advancement

Wallstreetcn

In the "Pharmaceutical Spring Festival Gala" in the United States, Chinese pharmaceutical companies have transformed from "optional consumption" to "essential consumption."

China Meheco's subsidiary Tianfang Pharmaceutical Co., Ltd. participated in the bidding for the 11th batch of national centralized drug procurement, with its Nicardipine tablets expected to be selected, specifications of 5mg, priced at 2.59 yuan/box, with a procurement period of 3 years. Tianfang Pharmaceutical's audited operating income for 2024 is approximately 52.47 million yuan. If successful in the bid, it will help expand sales scale, increase market share, and have a positive impact on the company's future performance

Zhitong

China Meheco: Subsidiary Tianfang Pharmaceutical's Nicardipine Tablets intend to be selected for the 11th batch of national centralized drug procurement

On May 16, 2025, China Meheco Health Industry Co., Ltd. approved the proposal on "Conducting Company Bond and Super Short-term Financing Bond Registration" at the 2024 Annual Shareholders' Meeting. Recently, the company received the "Registration Acceptance Notice" from the National Association of Financial Market Institutional Investors, accepting its super short-term financing bond registration amount of 3 billion yuan, with a registration validity of 2 years, co-led by 7 banks including China Merchants Bank and Industrial and Commercial Bank of China. The company may issue in installments during the registration validity period, and will disclose the results after the issuance is completed, fulfilling its information disclosure obligations as required

China Meheco's 3 billion ultra-short-term financing bond registration accepted by the Association of Dealers

On September 24th, China Meheco signed a strategic cooperation framework agreement with the government of Faku County. According to the agreement, both parties will carry out in-depth cooperation in areas such as the development of the pharmaceutical and healthcare industry and empowering the construction of closely-knit county-level medical communities

China Meheco signed a strategic cooperation framework agreement with the Faku County Government

On September 19th, Temasek Holdings and other investment institutions visited the National Healthcare Security Administration to discuss healthcare support for the high-quality development of China Meheco. The National Healthcare Security Administration stated that it will continue to implement relevant policies, utilize healthcare funds, policies, and data resources to promote the development of pharmaceutical institutions and drug innovation, and welcome domestic and foreign investment institutions to pay attention to the Chinese pharmaceutical industry. Participating institutions included AXA Investment Managers, Temasek Holdings, and others

Some domestic and foreign investment institutions visited the National Healthcare Security Administration

China Meheco's wholly-owned subsidiary Tianfang Pharmaceutical recently received approval from the National Medical Products Administration, with its Lincomycin Hydrochloride Injection passing the consistency evaluation for generic drugs. This medication is primarily used to treat severe infections caused by sensitive strains of bacteria. After passing the consistency evaluation, this drug will receive greater support in areas such as medical insurance payments and procurement by medical institutions, helping to enhance market competitiveness and expand market share

China Meheco's subsidiary has passed the consistency evaluation of the generic drug Lincomycin Hydrochloride Injection

301017

600272

603883

300937

The pharmaceutical commercial sector experienced a surge, with China Meheco hitting the daily limit, followed by Liuyao Group, SYPM, SHKK, LBX, and Hezong Medicine Easy-To-Buy Pharmaceutical rising in tandem

SYPM

SHKK

Hezong Medicine Easy-To-Buy Pharmaceutical

The pharmaceutical commercial sector experiences a surge, China Meheco hits the daily limit up

The Ministry of Industry and Information Technology held a symposium for pharmaceutical manufacturing enterprises, emphasizing the promotion of artificial intelligence applications across the entire pharmaceutical industry chain, enhancing corporate innovation capabilities, protecting intellectual property rights, and promoting orderly competition. Minister Li Lecheng pointed out the need to accelerate the high-quality development of the pharmaceutical industry, enhance the resilience of the industrial chain, encourage entrepreneurial spirit and social responsibility, promote innovative research and development, and elevate Chinese pharmaceutical brands

Ministry of Industry and Information Technology: Promote the deep empowerment of artificial intelligence in the entire pharmaceutical industry chain and guide enterprises to compete in an orderly manner in accordance with laws and regulations

China Meheco announced that in the first half of 2025, operating revenue was 17.076 billion yuan, a year-on-year decrease of 6.71%; net profit was 294 million yuan, a year-on-year decrease of 16.19%. The company plans to distribute a cash dividend of 0.1966 yuan for every 10 shares to all shareholders, with a total profit distribution of 29.409 million yuan

China Meheco: Net profit of 294 million yuan in the first half of 2025, a year-on-year decrease of 16.19%

China Meheco(600056.SH)